Resalis' lead investigational candidate is RES-010, which represents a first-in-class antisense oligonucleotide targeting miR-22, a non-coding RNA that plays a pivotal role in the molecular pathways underlying obesity. As of Q4 2024, Resalis is advancing RES-010 through a Phase II proof-of-concept clinical trial. 

Resalis is supported by investors Claris Ventures and Sunstone Life Science Ventures and private investors from Italian Angels for Growth and Club degli Investitori.